lobbying_activities: 1146905

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1146905	aaf6fb28-78f1-4f01-90b5-e8ab7fc8663d	Q3	ACADEMY OF MANAGED CARE PHARMACY	48793	ACADEMY OF MANAGED CARE PHARMACY	2011	third_quarter	PHA	S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act S 296 and HR 2245 - legislation that would address shortages of prescription drugs HR 2746 - legislation that would require cost-sharing parity between all cancer medications within pharmacy benefits regulated under ERISA. HR 979 - legislation that would implement transparency standards and other regulations for pharmacy benefit managers working within the Federal Employees Health Benefits Program.	HOUSE OF REPRESENTATIVES,SENATE		190000	0	0	2011-10-12T10:14:35.163000-04:00